Gamida Cell Presents Data Demonstrating the Impact of Transp

12.09.2022 - Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the presentation of data supporting the potential of omidubicel ... Seite 1

Related Keywords

Florida , United States , South Beach , Julian Adams , Gamida Cell Ltd , Nasdaq , Gamida Cell Presents Data Demonstrating , Hematologic Malignancies , Blood Connect Meeting , Related Quality , Following Transplantation , Omidubicel Versus Umbilical Cord Blood , Hematological Malignancies , Multicenter Study , Functional Assessment , Cancer Therapy General , Business Wire , Gamida Cell ,